Results 251 to 260 of about 99,451 (312)

Risk stratification and anal cancer screening in immunocompetent women with genital HPV: Value of multicentric HSIL and performance of HPV‐based screening

open access: yesInternational Journal of Cancer, Volume 159, Issue 4, Page 1017-1027, 15 August 2026.
What's new? Anal squamous cell carcinoma (ASCC) incidence is increasing, with most cases occurring in immunocompetent women. ASCC risk is linked in particular to genital human papillomavirus (HPV) infection and HPV‐associated high‐grade squamous intraepithelial lesions (HSILs).
Isabel Matas   +13 more
wiley   +1 more source

Oral squamous cell carcinoma presenting as a cervical lymphadenopathy.

open access: yesAnnali di stomatologia, 2013
S. Sutera   +4 more
openaire   +2 more sources

Nationwide Study on the Cervical Cancer Screening Pathway in Estonia

open access: yesInternational Journal of Cancer, Volume 159, Issue 4, Page 883-895, 15 August 2026.
Cervical cancer remains a significant burden despite being preventable, largely due to inadequate screening participation and poor follow‐up of high‐risk women. Here, the authors investigated follow‐up rates among women who tested positive for high‐risk human papillomavirus (hr‐HPV) infection in primary screening in Estonia. Data show that more than 57
Aleksandra Šavrova   +6 more
wiley   +1 more source

TCF/LEF family transcription factors: Molecular landscape and prognostic scoring in pan‐cancer

open access: yesClinical and Translational Discovery, Volume 6, Issue 4, August 2026.
This study provides a comprehensive molecular landscape of TCF/LEF family transcription factors across 33 cancer types. We developed a TCF/LEF‐based prognostic score that correlates with immune infiltration, metabolic reprogramming and drug sensitivity, offering a robust transcriptomic signature for predicting patient survival and therapeutic response.
Zhengjun Yang   +8 more
wiley   +1 more source

Coronavirus disease 2019 infection reduces EGFR‐TKI efficacy in non‐small cell lung carcinoma: Real‐world evidence from a multicenter propensity‐matched cohort

open access: yesInternational Journal of Cancer, Volume 159, Issue 3, Page 699-708, 1 August 2026.
What's New? Lung cancer patients with COVID‐19 experience significantly increased risk for severe illness and mortality. However, research addressing the effect of COVID‐19 on non‐small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) remains unknown.
Wenjie Tang   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy